Cancer drug treatment deal must be reached

It is devastating to hear that Kadcyla, a crucial life-extending treatment for those with incurable secondary breast cancer, faces being withdrawn from the NHS, following the failure of NICE and the drug's manufacturer, Roche, to reach an agreement.

Tuesday, 31st January 2017, 1:57 pm
Updated Tuesday, 31st January 2017, 2:01 pm

Kadcyla can offer patients precious extra months, even years, of good quality time with their loved ones, with fewer side effects than other treatments.

It is available in many other countries, including France, Germany and Australia.

Unless NICE’s draft decision is overturned next month, this fantastic medical advance will bypass patients in England forever.

Sign up to our daily newsletter

The i newsletter cut through the noise

That’s why I’ve backed Breast Cancer Now’s campaign to #KeepKadcyla.

It calls on NICE and Roche to urgently reach a deal to ensure patients in England are not denied it.

I urge NICE and Roche to do everything in their power to keep this drug available.

Neil Griffin,

Front Street,

Pity Me.